MX374944B - Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. - Google Patents

Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.

Info

Publication number
MX374944B
MX374944B MX2016008429A MX2016008429A MX374944B MX 374944 B MX374944 B MX 374944B MX 2016008429 A MX2016008429 A MX 2016008429A MX 2016008429 A MX2016008429 A MX 2016008429A MX 374944 B MX374944 B MX 374944B
Authority
MX
Mexico
Prior art keywords
inflammatory disease
metabolic syndrome
pharmaceutical composition
phenol derivative
pyranocromenyl
Prior art date
Application number
MX2016008429A
Other languages
English (en)
Spanish (es)
Other versions
MX2016008429A (es
Inventor
In Geun Jo
Jeong Ho Im
Jin Wook Chung
Jin Young Kim
Ku Suk Kang
Sang Ku Yoo
Original Assignee
Glaceum Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaceum Inc filed Critical Glaceum Inc
Publication of MX2016008429A publication Critical patent/MX2016008429A/es
Publication of MX374944B publication Critical patent/MX374944B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2016008429A 2013-12-24 2014-12-23 Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. MX374944B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130162909 2013-12-24
KR1020140181951A KR102344479B1 (ko) 2013-12-24 2014-12-17 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
PCT/KR2014/012688 WO2015099392A1 (ko) 2013-12-24 2014-12-23 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
MX2016008429A MX2016008429A (es) 2017-02-23
MX374944B true MX374944B (es) 2025-03-06

Family

ID=53788040

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008429A MX374944B (es) 2013-12-24 2014-12-23 Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.

Country Status (21)

Country Link
US (1) US9783551B2 (enExample)
EP (1) EP3098224B1 (enExample)
JP (2) JP6620096B2 (enExample)
KR (1) KR102344479B1 (enExample)
CN (1) CN105849111B (enExample)
AU (1) AU2014370697B2 (enExample)
BR (1) BR112016011281B1 (enExample)
CA (1) CA2929001C (enExample)
CY (1) CY1121554T1 (enExample)
DK (1) DK3098224T3 (enExample)
ES (1) ES2718878T3 (enExample)
HR (1) HRP20190573T1 (enExample)
HU (1) HUE043902T2 (enExample)
IL (1) IL245908B (enExample)
MX (1) MX374944B (enExample)
NZ (1) NZ720328A (enExample)
PL (1) PL3098224T3 (enExample)
PT (1) PT3098224T (enExample)
SG (1) SG11201604371PA (enExample)
TW (1) TWI585093B (enExample)
WO (1) WO2015099392A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물
TWI731998B (zh) 2016-06-29 2021-07-01 南韓商格雷森伍股份有限公司 光學活性吡喃並苯並吡喃基苯酚衍生物及包含其的醫藥組成物
TWI641610B (zh) * 2016-10-04 2018-11-21 南韓商格雷森伍股份有限公司 用於合成3-苯基-2,3,4,8,9,10-六氫吡喃並[2,3-f]色烯衍生物及其光學異構物的方法
TWI804600B (zh) * 2018-04-03 2023-06-11 南韓商格雷森伍股份有限公司 3-苯基-2,8-二氫吡喃[2,3-ƒ]苯并哌喃衍生物的合成方法
WO2019194583A1 (ko) * 2018-04-03 2019-10-10 주식회사 글라세움 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물
KR20200105198A (ko) * 2019-02-28 2020-09-07 주식회사 글라세움 신경계 질환의 예방 또는 치료용 약학적 조성물
KR102692932B1 (ko) 2019-07-30 2024-08-07 주식회사 글라세움 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법
US20250367163A1 (en) 2021-06-08 2025-12-04 Glaceum, Inc. Pharmaceutical composition for preventing or treating degenerative eye diseases
CN113616548B (zh) * 2021-09-02 2023-04-28 河南科技大学 一种水溶性光甘草定包合物及其制备方法
CN119343351A (zh) 2022-04-12 2025-01-21 格拉斯如睦株式会社 用于3-苯基-2,3,4,8,9,10-六氢吡喃并[2,3-f]色烯衍生物的合成方法
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途
KR20240113389A (ko) 2023-01-12 2024-07-22 주식회사 글라세움 퇴행성 골관절염의 예방 또는 치료용 약학적 조성물
KR20250081177A (ko) 2023-11-29 2025-06-05 한국화학연구원 Hsg4112 r형을 유효성분으로 포함하는 반려동물의 비만 예방, 개선 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050035142A (ko) * 2001-10-11 2005-04-15 카네카 코포레이션 페록시좀 증식제 응답성 수용체 리간드제 및 그 제조 방법
KR100565423B1 (ko) * 2003-10-20 2006-03-30 빅 바이오 주식회사 이소플라반 유도체 또는 이소플라벤 유도체의 제조방법
JP2006008604A (ja) * 2004-06-25 2006-01-12 Kuraray Co Ltd イソフラバン誘導体の製造方法
WO2007058480A1 (en) 2005-11-16 2007-05-24 Md Bioalpha Co., Ltd. Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin
KR102344479B1 (ko) * 2013-12-24 2021-12-29 주식회사 글라세움 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물

Also Published As

Publication number Publication date
CN105849111A (zh) 2016-08-10
KR102344479B1 (ko) 2021-12-29
PL3098224T3 (pl) 2019-07-31
JP6620096B2 (ja) 2019-12-11
NZ720328A (en) 2018-02-23
ES2718878T3 (es) 2019-07-05
PT3098224T (pt) 2019-04-26
MX2016008429A (es) 2017-02-23
DK3098224T3 (da) 2019-05-13
CN105849111B (zh) 2018-05-04
HUE043902T2 (hu) 2019-10-28
JP2018135343A (ja) 2018-08-30
BR112016011281B1 (pt) 2021-11-16
AU2014370697B2 (en) 2017-01-19
US9783551B2 (en) 2017-10-10
EP3098224A4 (en) 2017-07-05
US20160272650A1 (en) 2016-09-22
SG11201604371PA (en) 2016-07-28
IL245908B (en) 2020-08-31
EP3098224A1 (en) 2016-11-30
KR20150075030A (ko) 2015-07-02
BR112016011281A2 (enExample) 2017-08-08
JP2017501163A (ja) 2017-01-12
EP3098224B1 (en) 2019-01-30
CA2929001C (en) 2018-02-20
TW201607949A (zh) 2016-03-01
HRP20190573T1 (hr) 2019-05-17
IL245908A0 (en) 2016-08-02
CY1121554T1 (el) 2020-05-29
AU2014370697A1 (en) 2016-06-16
WO2015099392A1 (ko) 2015-07-02
CA2929001A1 (en) 2015-07-02
TWI585093B (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
CY1121554T1 (el) Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
PT4000608T (pt) Composição farmacêutica, métodos para o tratamento e suas utilizações
NI201600071A (es) Compuestos de inhibidor de autotaxina
PH12016500024A1 (en) Bromodomain inhibitor
BR112016010564A2 (pt) terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
JOP20140104B1 (ar) مركبات ثنائى اريل اميد كمثبطات كيناز
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
KR101894521B9 (ko) 흉터치료를 위한 국소용 약학적 조성물
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GLACEUM, INC.

FG Grant or registration